The EMA at 20: A quality model that deserves to be replicated
This article was originally published in Scrip
Despite initial industry misgivings, the European Medicines Agency has been a huge success, and initiatives like adaptive pathways and greater patient involvement show it is not resting on its laurels. But more could be done in areas such as pharmacovigilance, priority reviews and co-ordination among the agency's committees, say EFPIA's Richard Bergström and Pär Tellner.
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.